BioSpace News Archive

Health Canada has contacted companies that may be importing or distributing certain respirators, including KN95 respirators, in Canada that may not meet safety and effectiveness standards to request that they immediately stop sale and relabel current stock as face masks (not respirators).

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced the pricing of its previously announced underwritten public offering of 3,676,471 shares of its common stock at a price to the public of $34.00 per share.

Illumina, Inc. is paving the way for large-scale, next-generation sequencing-based COVID-19 testing.

As pharmaceutical manufacturers work to develop a coronavirus vaccine, the demand for clinical research associates and trial managers has risen by 46 percent – making it one of the few industries to increase hiring since the start of the pandemic – according to a COVID-19 impact analysis report released today by global talent mobility provider

Patent issuance protects the Boltbody™ ISAC technology platform as a potentially disruptive solution to the challenges facing current oncology therapeutics [09-June-2020] REDWOOD CITY, Calif. , June 9, 2020 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a private clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform tec

FUJIFILM Corporation will make a major capital investment of approximately 100 billion yen in the Denmark site of FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization for biologics and advanced therapies.

RapidAI, the worldwide leader in advanced imaging for stroke, today announced the acquisition of EndoVantage, developer of the Find, Track and Treat™ comprehensive cerebral aneurysm management platform. A major neurological condition, it is estimated that 1 in 50 p

These important proof-of-concept studies could one day lead to new real-time diagnostic imaging techniques and the identification of genomic biomarkers that predict treatment results – innovations that will improve health outcomes for cancer patients DUARTE, Calif.--( BUSINESS WIRE )-- City of Hope scientists will showcase research at the AACR Virtual Annual Meeting II that could one day lead to real-time diagnostic imaging and leading-edge genomic

Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a laboratory developed test for worldwide commercial availability by Mayo Clinic Labo

Corporate Screening Services, Inc., a leader in healthcare pre-employment background screening, is pleased to announce the release of CS SafeGuard, a real-time product developed with the healthcare industry in mind.